Use of Cis-[18F]Fluoro-Proline for Assessment of Exercise-Related Collagen Synthesis in Musculoskeletal Connective Tissue

Protein turnover in collagen rich tissue is influenced by exercise, but can only with difficulty be studied in vivo due to use of invasive procedure. The present study was done to investigate the possibility of applying the PET-tracer, cis-[18F]fluoro-proline (cis-Fpro), for non-invasive assessment of collagen synthesis in rat musculoskeletal tissues at rest and following short-term (3 days) treadmill running. Musculoskeletal collagen synthesis was studied in rats at rest and 24 h post-exercise. At each session, rats were PET scanned at two time points following injection of cis-FPro: (60 and 240 min p.i). SUV were calculated for Achilles tendon, calf muscle and tibial bone. The PET-derived results were compared to mRNA expression of collagen type I and III. Tibial bone had the highest SUV that increased significantly (p<0.001) from the early (60 min) to the late (240 min) PET scan, while SUV in tendon and muscle decreased (p<0.001). Exercise had no influence on SUV, which was contradicted by an increased gene expression of collagen type I and III in muscle and tendon. The clearly, visible uptake of cis-Fpro in the collagen-rich musculoskeletal tissues is promising for multi-tissue studies in vivo. The tissue-specific differences with the highest basal uptake in bone are in accordance with earlier studies relying on tissue incorporation of isotopic-labelled proline. A possible explanation of the failure to demonstrate enhanced collagen synthesis following exercise, despite augmented collagen type I and III transcription, is that SUV calculations are not sensitive enough to detect minor changes in collagen synthesis. Further studies including kinetic compartment modeling must be performed to establish whether cis-Fpro can be used for non-invasive in-vivo assessment of exercise-induced changes in musculoskeletal collagen synthesis

Mycotoxins in the ventilation systems of four schools in Finland

Some fungal species have been listed as a problem causing fungi in indoor air and most of this group are known to produce mycotoxins. So far, mycotoxins have been found in building materials and in samples representing settled indoor air dust, as well in air samples from industrial or agricultural environments. The present paper presents the results of a mycological study and mycotoxin analyses of dust collected from mechanical ventilation systems in four school buildings in southern Finland. The aim of this work was to answer the question 'Are there mycotoxins in ventilation systems and if so, from where do they originate?' A total of 40 mycotoxins representing indoor and outdoor sources alike were screened in this study, while cultivable fungi were screened using four different cultivation media. Mycotoxins were present in all ventilation systems studied, both in the supply and the exhaust systems examined. The mycotoxins found included satratoxins, verrucarol, trichodermol, enniatins, beauvericin, penicillic acid, sterigmatocystin, chaetoglobosin A, and aflatoxins B-1. The mycotoxins were present in minute quantities (pg-ng/g or pg-ng/cm(2)). The fungal genera associated with respective mycotoxins were found in most of the same sources. Since much the same mycotoxins could be established in both exhaust and supply air systems, it would appear that the mycotoxins found in the schools studied do not for the most part originate from sources within the building but are either normal artefacts of incoming supply air or concentrate or are perhaps produced within the ventilation systems due to infrequent changing of filters and maintenance/cleaning of ventilation ducts and associated parts of the systems

Personalizing health care: feasibility and future implications

Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and companies may seek high prices for new targeted drugs. There is a need to integrate current knowledge from a payer’s perspective to provide future guidance. Multiple findings including general considerations; influence of pharmacogenomics on response and toxicity of drug therapies; value of biomarker tests; limitations and costs of tests; and potentially high acquisition costs of new targeted therapies help to give guidance on potential ways forward for all stakeholder groups. Overall, personalized medicine has the potential to revolutionize care. However, current challenges and concerns need to be addressed to enhance its uptake and funding to benefit patients